Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07617870 Recombinant human prourokinase Ischemic Attack, Transient Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617870 Recombinant human prourokinase Ischemic Attack, Transient Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07617870 clinical trial report covering Recombinant human prourokinase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07619131 Rosuvastatin Calcium Hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07619131 Rosuvastatin Calcium Hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07619131 clinical trial report covering Rosuvastatin Calcium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07619118 Rosuvastatin Calcium Hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07619118 Rosuvastatin Calcium Hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07619118 clinical trial report covering Rosuvastatin Calcium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07618806 Amlodipine Besylate Tumescence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07618806 Amlodipine Besylate Tumescence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07618806 clinical trial report covering Amlodipine Besylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261932 Eloralintide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261932 Eloralintide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261932 clinical trial report covering Eloralintide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262081 HY-072808 Chronic hand eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262081 HY-072808 Chronic hand eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20262081 clinical trial report covering HY-072808, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261945 Chaijin Jieyu Anshen Tablets Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261945 Chaijin Jieyu Anshen Tablets Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261945 clinical trial report covering Chaijin Jieyu Anshen Tablets, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07621718 Zoldonrasib Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07621718 Zoldonrasib Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07621718 clinical trial report covering Zoldonrasib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07620574 Enzalutamide Well Differentiated Pancreatic Endocrine Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07620574 Enzalutamide Well Differentiated Pancreatic Endocrine Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07620574 clinical trial report covering Enzalutamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07619833 Enavogliflozin Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07619833 Enavogliflozin Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07619833 clinical trial report covering Enavogliflozin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262177 NHL35700 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262177 NHL35700 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20262177 clinical trial report covering NHL35700, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07621809 Ianalumab Sjogren's Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07621809 Ianalumab Sjogren's Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07621809 clinical trial report covering Ianalumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →